Evicenter
Kisqali (ribociclib) in HR-positive HER2-negative advanced or metastatic breast cancer
Manufacturer
Novartis Pharmaceuticals Corporation
Prescribing information
Kisqali (opens in a new tab)
Questions
57
Last updated

All questions

Clinical trials: Kisqali (ribociclib) in HR-positive HER2-negative advanced or metastatic breast cancer

12 questions · 8 sources

Study results

Do patients live longer on Kisqali plus letrozole vs letrozole alone (MONALEESA-2)?

Applies to Postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer and no prior therapy for advanced disease, with letrozole (MONALEESA-2)

How long did Kisqali plus letrozole delay progression vs letrozole alone (MONALEESA-2)?

Applies to Postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer and no prior therapy for advanced disease, with letrozole (MONALEESA-2)

Note: The first two passages are from the KISQALI Access Support Guide that the Novartis Patient Support page links; the third is Table 19 of the Prescribing Information.

Who was studied in the Kisqali MONALEESA-2 trial?

Applies to Postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer and no prior therapy for advanced disease, with letrozole (MONALEESA-2)

Do patients live longer on Kisqali plus fulvestrant vs fulvestrant alone (MONALEESA-3)?

Applies to Postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer and no or one prior line of endocrine therapy for advanced disease, with fulvestrant (MONALEESA-3)

How long did Kisqali plus fulvestrant delay progression vs fulvestrant alone (MONALEESA-3)?

Applies to Postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer and no or one prior line of endocrine therapy for advanced disease, with fulvestrant (MONALEESA-3)

Note: The first two passages are from the KISQALI Access Support Guide that the Novartis Patient Support page links; the third is Table 21 of the Prescribing Information, whose comparator arm is placebo plus fulvestrant.

Do premenopausal women live longer on Kisqali plus an NSAI and goserelin (MONALEESA-7)?

Applies to Pre- and perimenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer and no prior endocrine therapy for advanced disease, with a nonsteroidal aromatase inhibitor and goserelin (MONALEESA-7)

“MONALEESA-7 was a randomized, double-blind, placebo-controlled, phase III study of KISQALI + ET (NSAI or tamoxifen) + goserelin (n=335) vs placebo + ET (NSAI or tamoxifen) + goserelin (n=337) (ITT) in premenopausal patients with HR+/HER2- mBC who received no prior ET for advanced disease. KISQALI is not indicated for concomitant use with tamoxifen. Efficacy results are from a prespecified subgroup analysis of 495 patients who received KISQALI (n=248) or placebo (n=247) with an NSAI + goserelin. OS was a secondary end point; PFS was the primary end point. In the prespecified OS analysis at a median follow-up of 35 months, mOS was not reached with KISQALI + NSAI + goserelin (95% CI: NR-NR) vs 40.7 months with placebo + NSAI + goserelin (95% CI: 37.4-NR); HR=0.699 (95% CI: 0.501-0.976). Statistical significance was established for overall survival in the ITT population; HR=0.71 (95% CI: 0.54-0.95); P=0.00973. At a median follow-up of 54 months (exploratory analysis), mOS was 58.7 months with KISQALI + NSAI + goserelin (95% CI: 48.5-NR) vs 47.7 months with placebo + NSAI + goserelin (95% CI: 41.2-55.4); HR=0.798 (95% CI: 0.615-1.035). Results from the 54-month analysis were not prespecified and were observational in nature; as such, there was no prespecified statistical procedure controlling for type 1 error.1,4,5,9,10” (opens the source at this quote in a new tab)

How long did Kisqali delay progression in premenopausal women (MONALEESA-7)?

Applies to Pre- and perimenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer and no prior endocrine therapy for advanced disease, with a nonsteroidal aromatase inhibitor and goserelin (MONALEESA-7)

Note: The first two passages are from the KISQALI Access Support Guide that the Novartis Patient Support page links; the third is Table 20 of the Prescribing Information (MONALEESA-7 NSAI subgroup), which gives the medians in months.

How long did Kisqali delay chemotherapy in premenopausal women (MONALEESA-7)?

Applies to Pre- and perimenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer and no prior endocrine therapy for advanced disease, with a nonsteroidal aromatase inhibitor and goserelin (MONALEESA-7)

Was survival different after Kisqali dose reduction in MONALEESA trials (post hoc analysis)?

“Across the 3 phase III MONALEESA clinical trials, overall survival (OS) was maintained for patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (mBC) who required dose reduction of KISQALI. These data are from a time-varying Cox regression analysis of OS by dose reduction. Results are based on a post hoc analysis; efficacy in the placebo comparator arms was not assessed and should be interpreted with caution1-5: In the MONALEESA-2 trial: 62.6% of patients (209/334) had ≥1 dose reduction. Median overall survival (mOS) was 66.0 months for patients with ≥1 dose reduction (95% CI: 57.6-75.7) vs 60.6 months for patients without dose reductions (95% CI: 42.5-79.2); HR=0.87 (95% CI: 0.65-1.18)1,2 In the MONALEESA-3 trial: 40.7% of patients (197/484) had ≥1 dose reduction. mOS was not reached for patients with ≥1 dose reduction (95% CI: 43-NR) vs not reached for patients without dose reductions (95% CI: 41.1-NR); HR=0.88 (95% CI: 0.64-1.21)3,4 In the MONALEESA-7 trial: 40.7% of patients (101/248) had ≥1 dose reduction. mOS was not reached for patients with ≥1 dose reduction (95% CI: NR-NR) vs not reached for patients without dose reductions (95% CI: NR-NR); HR=0.79 (95% CI: 0.46-1.36)3,5” (opens the source at this quote in a new tab)

On the page, select: Does reducing the KISQALI dose affect treatment effectiveness for patients with metastatic breast cancer?

Subgroup results

What was Kisqali overall survival by age group (pooled post hoc MONALEESA analysis)?

Applies to Patients with HR-positive, HER2-negative advanced or metastatic breast cancer in pooled analyses of MONALEESA-2, MONALEESA-3, and MONALEESA-7

What was overall survival with Kisqali plus fulvestrant in visceral metastases (MONALEESA-3)?

Applies to Postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer and no or one prior line of endocrine therapy for advanced disease, with fulvestrant (MONALEESA-3)

Note: The page presents this subgroup analysis for first- and second-line (1L/2L) postmenopausal patients from MONALEESA-3.

Comparative studies

How did Kisqali compare with chemotherapy in RIGHT Choice patients without visceral crisis?

Applies to Pre- and perimenopausal women with aggressive HR-positive, HER2-negative advanced or metastatic breast cancer, first-line, with an aromatase inhibitor and goserelin (RIGHT Choice)

Note: All efficacy figures on the page, including the response rates, are from the subgroup of patients without visceral crisis.